Retos actuales de la quimioterapia tras la Refractariedad al Tratamiento Hormonal en Cáncer de Mama Metastásico

7 / 24

Consider
chemotherapy
NCCN guidelines recommendations for the use of endocrine
therapy vs chemo in ER+/HER2- MBC
Sequential
endocrine therapy
Chemo
Visceral crisis
YES NO
Progression or unacceptable
toxicity
No clinical benefit after 3 consecutive endocrine
therapy regimens
HR+/HER2- ABC
NCCN. V1.2018